Tissue Modeling & Drug Development Shared Resources Core

摘要-组织建模与药物开发核心(共享资源) 佛罗里达-加州癌症研究、教育和参与(Care2)健康公平中心的目标 组织建模和药物开发核心(TMDDC)是提供不断增长的固定和活组织档案 这将支持Care2中心的使命。在第一个资助期(第一周期)，我们非常成功。 在获得FAMU和Care2研究人员访问黑人/非裔美国人注释组织(B/AA)方面 和西班牙裔/拉丁裔(H/L)。总体而言，TMDDC现在可以在整个合作伙伴关系中合规访问 肿瘤病例包括胰腺癌块(295B/AA，306H/L)，胰腺癌血浆/血清(136例 B/AA，53H/L)，前列腺癌阻断组(548B/AA，195H/L)，前列腺癌血浆/血清(595B/AA，92H/L)。 此外，TMDDC还促进了从B/AA创建或识别4个新的患者来源的异种移植物(PDX 在FAMU和南加州大学进行研究的胰腺癌患者。TMDDC将继续开发一个强大的、 注释良好的固定和活组织样本的生物储存库来自种族和民族多样化的佛罗里达州和 并将其提供给Care2调查人员。TMDDC将包括 现有的机构、国家共享和具有未来意识的生物库资源。的短期目标 TMDDC将为本申请所包括的三个项目提供必要的组织样本，同时 为现有和即将到来的Care2中心项目的未来需求做准备。TMC将解决 医学研究中招聘B/AA和H/L人才面临的挑战和有限的质量供应 这些种群的生物标本和基因组数据。我们的具体目标是：目标1.推进我们现有的 虚拟和物理存储库，将越来越多地提供来自不同肿瘤存储库的生物标本 通过Care2中心提供的单一接入点。许多癌症类型和许多组织模型是 与差异研究的结果相关。研究这些复合体所需的广泛类型的组织和数据 问题使得收购一个完全令人满意的储存库超出了任何单一机构的范围。因此， 我们将发展收集或获取新颖、多样和注释良好的标本的能力 机构资源和其他资源。目的2.获取活体肿瘤组织用于药物开发。PDX 已经证明比历史上使用的细胞系衍生研究更能预测人类的药物反应。发展 其中PDX具有促进快速药物开发的潜力，包括作为以下功能的测试反应 种族/血统。TMDDC将推进FAMU现有的Cycle 1开发的组织存储库。TMDDC 将在FAMU现有的活组织储存库上取得进展。通过实现这些目标，我们将：(1)加强 癌症差异组织模型研究；(2)为Care2研究人员扩大癌症差异资源， 以及(3)确保持续专注于转让技术诀窍、技术和与FAMU的合作。 评价的基础将是充分提供项目所需的标本/资源，并在 将药物开发技术和诀窍转让给FAMU。

ABSTRACT – TISSUE MODELING & DRUG DEVELOPMENT CORE (SHARED RESOURCE) The goal of the Florida-California Cancer Research, Education, & Engagement (CaRE2) Health Equity Center’s Tissue Modeling and Drug Development Core (TMDDC) is to provide a growing archive of fixed and living tissues that will support the mission of the CaRE2 Center. In the first funding period (Cycle 1), we were highly successful in gaining access for FAMU and CaRE2 researchers to annotated tissues from Black/African American (B/AA) and Hispanic/Latinx (H/L). In total, the TMDDC now has regulatory compliant access across the partnership to cancer cases including pancreatic cancer blocks (295 B/AA, 306 H/L), pancreatic cancer plasma/serum (136 B/AA, 53 H/L), prostate cancer blocks (548 B/AA, 195 H/L), and prostate plasma/serum (595 B/AA, 92 H/L). Also, the TMDDC facilitated creation or identification of 4 new patient-derived xenografts (PDX) from B/AA patients with pancreatic cancer for studies at FAMU and USC. The TMDDC will continue to develop a robust, well-annotated biorepository of fixed and living tissue samples from a racially and ethnically diverse Florida and California patient population and make them available to the CaRE2 investigators. The TMDDC will consist of existing institutional, nationally shared, and future-conscious biorepository resources. The short-term goals of the TMDDC are to provide the necessary tissue samples for the three projects included in this application, while preparing for the future needs of the existing and upcoming CaRE2 Center projects. The TMC will address the challenge of recruiting B/AA and H/L individuals in medical research and the limited supply of quality biospecimens and genomic data for these populations. Our specific aims are to: Aim 1. Advance our existing virtual and physical repositories that will increasingly provide biospecimens from diverse tumor repositories through a single access point provided by the CaRE2 Center. Many cancer types and many tissue models are relevant to outcomes in disparities research. The broad types of tissues and data required to study these complex issues make acquisition of a fully satisfactory repository beyond the scope of any single institution. Therefore, we will develop capabilities to collect or acquire novel diverse and well annotated specimens through our institutional resources and other resources. Aim 2. Acquire living tumor tissue for drug development. PDXs have proven to better predict human drug responses than historically used cell-line derived studies. Development of these PDXs has the potential to facilitate rapid drug development, including testing response as a function of race/ancestry. The TMDDC will advance the existing Cycle 1 developed tissue repository at FAMU. The TMDDC will advance on the existing living tissue repository at FAMU. By achieving these aims, we will: (1) enhance cancer disparities tissue-modeling research; (2) expand cancer disparities resources for CaRE2 researchers, and (3) ensure a sustained focus on transferring know-how, technology, and collaborations with FAMU. Evaluation will be based on adequate provision of project-required specimens/resources and by success in transferring drug development technology and knowhow to FAMU.